BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 19167838)

  • 1. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated Radiosurgery Plus Bevacizumab for Locally Recurrent Brain Metastasis with Previously High-Dose Irradiation.
    Guan Y; Wang C; Zhu H; Li J; Xu W; Sun L; Pan L; Dai J; Wang Y; Wang E; Wang X
    World Neurosurg; 2020 Jan; 133():e252-e258. PubMed ID: 31505283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
    Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.
    Zuniga RM; Torcuator R; Jain R; Anderson J; Doyle T; Ellika S; Schultz L; Mikkelsen T
    J Neurooncol; 2009 Feb; 91(3):329-36. PubMed ID: 18953493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
    Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
    Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study.
    Sahebjam S; Forsyth PA; Tran ND; Arrington JA; Macaulay R; Etame AB; Walko CM; Boyle T; Peguero EN; Jaglal M; Mokhtari S; Enderling H; Raghunand N; Gatewood T; Long W; Dzierzeski JL; Evernden B; Robinson T; Wicklund MC; Kim S; Thompson ZJ; Chen DT; Chinnaiyan P; Yu HM
    Neuro Oncol; 2021 Apr; 23(4):677-686. PubMed ID: 33173935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study.
    Park KJ; Kano H; Iyer A; Liu X; Niranjan A; Flickinger JC; Lieberman FS; Lunsford LD; Kondziolka D
    J Neurooncol; 2012 Apr; 107(2):323-33. PubMed ID: 22057917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma.
    Vordermark D; Kölbl O; Ruprecht K; Vince GH; Bratengeier K; Flentje M
    BMC Cancer; 2005 May; 5():55. PubMed ID: 15924621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
    Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.
    Fogh SE; Andrews DW; Glass J; Curran W; Glass C; Champ C; Evans JJ; Hyslop T; Pequignot E; Downes B; Comber E; Maltenfort M; Dicker AP; Werner-Wasik M
    J Clin Oncol; 2010 Jun; 28(18):3048-53. PubMed ID: 20479391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.
    Ali SA; McHayleh WM; Ahmad A; Sehgal R; Braffet M; Rahman M; Bejjani G; Friedland DM
    J Neurosurg; 2008 Aug; 109(2):268-72. PubMed ID: 18671639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
    Buie LW; Valgus J
    Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
    Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?
    Fokas E; Wacker U; Gross MW; Henzel M; Encheva E; Engenhart-Cabillic R
    Strahlenther Onkol; 2009 Apr; 185(4):235-40. PubMed ID: 19370426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
    Cohen MH; Shen YL; Keegan P; Pazdur R
    Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
    Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
    J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.